Latest announcement is potentially a big earner for PSD in years to come.....this kind of diagnostics technology is a huge leap forward (and cheap to administer!!). Current testing for monitoring existing or diagnosing new cancers is either costly & time consuming (electrophoresis methods) or moderately pricey chemical methods which are limited (and also not very cheap) in the types of cancer activity which can be individually screened for. There is a GREAT need for increased capeability in this area. PSD will have it all.....from diagnostics to treatment......an amazing Company IMHO!!
Regards
Drewe.
PSD Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
